Pharmaceutical & Biotech Quality Leadership

Kenneth P. Bonnell

Chief Quality Officer  ·  SVP Quality & Regulatory Affairs  ·  Global Compliance Leader

More than thirty years safeguarding patients across biotechnology, sterile manufacturing, CDMOs, and Big Pharma — through FDA inspection excellence, Warning Letter remediation, and the building of quality organizations that endure.

30+
Years in Quality Leadership
Zero-483
Multiple FDA Inspection Outcomes
Warp Speed
COVID-19 Vaccine Quality Lead
5
Drug Master Files Filed
Kenneth P. Bonnell, Chief Quality Officer
01 — Executive Summary

A quality leader built for the highest-stakes environments.

I am a senior pharmaceutical quality executive with more than thirty years of progressive leadership across biotechnology, sterile manufacturing, CDMOs, and Big Pharma. My career has been defined by a single conviction: that quality is, at its core, a patient-safety mission.

I bring a proven record of FDA inspection excellence — including multiple zero-observation outcomes and successful Warning Letter remediation. I was recruited for Project Warp Speed to lead quality operations supporting COVID-19 vaccine production at Aldevron. My expertise spans 503B sterile compounding, biologics, vaccines, medical devices, and clinical trial management.

A Six Sigma Black Belt, I pair strategic vision with deep tactical command across every quality discipline — validation, metrology, microbiology, chemistry, environmental monitoring, regulatory affairs, supplier quality, batch release, internal auditing, and SOP management — and I lead teams that take ownership of compliance rather than fear it.

02 — Core Competencies

Command across every quality discipline.

/01

Quality & Regulatory Leadership

FDA / CBER / CDER InspectionsGlobal Regulatory StrategyWarning Letter RemediationDMF / BLA / IND / ANDA / NDA FilingsHealth Authority InteractionsQuality System TransformationP&L ManagementSite Master Files
/02

Manufacturing & Operations

Sterile ManufacturingAseptic ProcessingMedia FillsPotent Compound ManufacturingVaccine ManufacturingRx & OTC Drug ManufacturingClinical Trial ManagementDEA & Controlled Substances
/03

Quality Control & Laboratory

MicrobiologyQC ChemistryEnvironmental MonitoringUSP & Compendial TestingMethod Development & ValidationStability ProgramsAnalytical Method ValidationGLP
/04

Compliance & Systems

cGMP / GLP / GCPIQ / OQ / PQ QualificationComputer System Validation21 CFR Part 11Data Integrity / ALCOA+Metrology & CalibrationChange ControlCAPA ManagementRoot Cause Analysis
/05

Quality Assurance

Incoming Quality AssuranceSupplier Quality ManagementVendor AuditingQuality AgreementsBatch ReleaseSOP DevelopmentInternal AuditingContamination Control StrategyICH Q9 Risk ManagementGAMP 5
03 — Signature Achievements

The work I am proudest of.

i

Project Warp Speed

Recruited to lead quality operations supporting COVID-19 vaccine production at Aldevron during the global pandemic — quality work performed at speed, at scale, and under national scrutiny.

ii

Zero-Observation FDA Inspections

Delivered multiple zero-observation outcomes across my career — including Aldevron's first FDA inspection achieving zero observations and NAI status, and three successive zero-483 inspections at PCI Pharma Services.

iii

Warning Letter Remediation

Recruited to Teligent Pharma to remediate an FDA Warning Letter and restore compliance across global operations — meeting directly with FDA's Office of Regulatory Affairs throughout the process.

iv

“Best in Class” — MHRA

Re-executed site cleaning validation at PCI in under nine months, reducing TAMC values from 10 PPM to under 2 PPM — a process the MHRA photographed as an example of “best in class.”

v

Founder to Acquisition

Founded Alpha-Omega, growing it with triple-digit year-over-year growth to acquisition by VWR International — and was named SBA Businessperson of the Year, with recognition in the Wall Street Journal.

04 — Professional Experience

Career history.

April 2024 — Present

Chief Quality Officer

SCA Pharma, LLC / Windsor, CT & Little Rock, AR
503B outsourcing facility specializing in sterile compounding of injectable pharmaceuticals.
  • Lead all Quality Assurance, Quality Control, and Regulatory Affairs across two FDA-registered sterile manufacturing facilities producing compounded sterile preparations (CSPs).
  • Developed and implemented a comprehensive Contamination Control Strategy (CCS) aligned with FDA 503B CGMP guidance, FDA aseptic processing guidance, USP <797>, <71>, <85>, <1116>, and EU Annex 1.
  • Strengthened environmental monitoring — viable and non-viable particulate, surface sampling, personnel monitoring, and trending analysis.
  • Enhanced aseptic processing controls including media fill protocols, gowning qualification, and aseptic technique training.
  • Restructured deviation investigations with robust root cause analysis (fishbone, 5-Why, Kepner-Tregoe), comprehensive CAPA, and effectiveness verification.
  • Manage QC laboratory operations — sterility, endotoxin, potency assays, and release testing — and the supplier quality program including vendor qualification and Quality Agreements.
July 2020 — August 2023

SVP & Global Head of Quality, Regulatory Affairs & Compliance

Aldevron, LLC (A Danaher Company) / Fargo, ND & Madison, WI
Leading CDMO for plasmid DNA, mRNA, and proteins; recruited as part of Project Warp Speed during the global pandemic.
  • Led all QC (Biochemistry, Sequencing, Environmental Monitoring, Microbiology), QA (Incoming, Operational, Product Release, GMP Training), Regulatory Affairs (DMF, BLA, IND; CBER, Health Canada, EMA), and Compliance across all sites.
  • Achieved the site's first FDA inspection with zero observations and NAI status.
  • Reduced Quality takt time by more than 55% through Quality Function Deployment — internal testing capabilities, eliminating IQA oversampling, cross-training for flex-flow, and standardized work to reduce OOS events.
  • Filed five Drug Master Files including pALD-X80 (supercoiled dsDNA construct for AAV transfection); authored the Site Master File within six months.
  • Converted the Madison facility from research-grade to GMP and secured ISO 13485 registration in only nine months.
  • Formed the Regulatory Affairs & Compliance Department within the first year and established a Quality Continuous Process Improvement group for permanent inspection readiness.
  • Developed standardized stability and release panels for pDNA, mRNA, master cell banks, and proteins (CRISPR Cas9); devised revenue-generating services that offset the cost of the Quality organization.
  • Drove transformation through Danaher Business System (DBS) tools and PSP; performed sitewide CSV, 21 CFR Part 11, and ALCOA+ assessment with full remediation planning.
May 2019 — June 2020

Vice President & Global Head of Quality

Teligent Pharma, Inc. / Buena, NJ
Global pharmaceutical company specializing in dermatological products and sterile injectables using aseptic and isolator technology.
  • Recruited to remediate an FDA Warning Letter and restore compliance across global operations; met directly with FDA's Office of Regulatory Affairs (ORA).
  • Restructured the deviation process with RCA tools, contemporaneous data collection, proper scoping, and patient-safety / product-quality impact assessments.
  • Harmonized Quality processes across US, Canada, and Estonia facilities; enhanced change control with pre-approval stage gates.
  • Re-executed sitewide cleaning validation and rewrote the Validation Master Plan and Cleaning Validation Master Plan.
  • Upgraded media fill and sterility assurance programs; updated environmental monitoring sampling maps in sterile core and topical areas; enhanced pharmacovigilance and FDA MedWatch reporting.
April 2013 — May 2019

Vice President, Global Quality, Regulatory & Compliance

PCI Pharma Services / Philadelphia, PA
Global technical-services CDMO for clinical trials (Phase I–IV), manufacturing, packaging, potent compounds, combination products, controlled substances, biologics, and serialization.
VP, Global Quality, Regulatory & Compliance (2017–2019)  ·  Executive Director, QA & Regulatory Affairs (2013–2017)
  • Promoted to VP after achieving three successive FDA inspections with zero 483 observations.
  • Achieved multiple successful international inspections: MHRA, Turkish Ministry of Health, ANVISA, EMA, Health Canada, and the Japanese Health Authority.
  • Re-executed site cleaning validation in under nine months, reducing TAMC from 10 PPM to under 2 PPM — photographed by MHRA as “best in class.”
  • Implemented customer-specific testing monographs reducing IQA nonconformances by more than 50%.
  • Redesigned Master Batch Records using Human Error Reduction principles, improving Right First Time from 88% to 98%+.
  • Managed controlled substances operations, DEA interactions, and required filings (ARCOS reports, Form 222); built a company-wide Quality Dashboard with statistical trending.
September 2008 — March 2013

Associate Director, Quality Assurance

Merck & Co., Inc. / West Point, PA
Global pharmaceutical company producing life-saving vaccines and medicines.
  • Cycled through Regulatory Affairs, GMP Compliance, Focus Factory Quality, and Site Quality across Sterile Supply, Pharmaceutical Operations, and the Biotechnology Manufacturing Complex.
  • Decreased sterilization and container-closure deviations by more than 60% through process redesign and Human Error Reduction principles.
  • Reduced document defects 47% and improved RFT metrics by more than 21%; led batch record redesign achieving 98%+ RFT for Pneumovax 23 and Gardasil.
  • Supported numerous inspections (FDA, MHRA, TGA, KFDA) and authored BLA and IND filing sections.
  • Won nine Awards for Excellence in four years.
August 2004 — April 2008

Operations / Quality Director, Technical Services

VWR International, LLC / Wilmington, DE
$3.5B global scientific supply company; acquired Alpha-Omega in 2004.
  • Built the division into a significant profit center through expansion of FDA- and GxP-compliant services; trained and led 55 employees nationally.
  • Guided medical device manufacturers through 510(k) and De Novo submissions; advised on IND, NDA, and ANDA applications.
  • Won the President's Club award — received by fewer than 2% of associates — after only one year.
  • Designed a Six Sigma–based CAPA program that eliminated 30% of customer complaints.
November 2001 — August 2004

CEO, President & Owner (Founder)

Alpha-Omega / Gibbstown, NJ
Provider of compliance, analytical testing, metrology, validation, process control, contract QC testing, and technical training services.
  • Founded and grew a validation and technical-services company with triple-digit year-over-year growth, securing acquisition by VWR International.
  • Oversaw P&L, operations, and a 20-person team of engineers, validation engineers, metrologists, and technicians.
  • Interfaced with FDA, MHRA, EMA, Turkish Ministry of Health, and Health Canada on filings (CBE-0, CBE-30, INDs, ANDAs, NDAs); built a world-class QC laboratory.
  • Innovated the Pipette Standards Handbook; named SBA Businessperson of the Year with recognition in the Wall Street Journal.
05 — Earlier Career

Foundational roles.

Henry Troemner, LLC

Technical Director · 1999–2001

Directed mass and pipette calibration laboratories, engineering, and product development. Implemented lean manufacturing eliminating 25% waste, improving on-time delivery 13% and productivity 30%. Conceptualized a pipette calibration program that expanded the business over 400% in two years; secured ISO/IEC 17025 accreditation and UL/CE approvals.

Cole-Parmer Instrument Company

Technical Services & Application Engineer · 1997–1999

Increased revenues over 75%, setting multiple company records. Promoted within one year and named Associate of the Year 1998. Managed equipment setup and validation projects including IQ/OQ/PQ protocol development and execution.

BISCO

QC Chemist / Microbiologist / Regulatory Compliance Manager · 1996–1997

Owned QC Microbiology, environmental monitoring, Incoming QA, and regulatory compliance for a medical device manufacturer. Released lots of dental adhesives and composites; ensured compliance to US FDA QSR and ISO 13485; prepared and submitted 510(k) premarket notifications.

06 — Awards & Recognition

Recognized work.

Aldevron

Zero-Observation FDA Inspection

First site inspection achieving zero observations and NAI status.

PCI · MHRA

“Best in Class” Cleaning Validation

Process photographed by the MHRA as an industry example.

Merck

Nine Awards for Excellence

Earned across four years of tenure.

VWR

President's Club

Awarded to fewer than 2% of associates — earned within one year.

Alpha-Omega

SBA Businessperson of the Year

Recognized in the Wall Street Journal.

Cole-Parmer

Associate of the Year, 1998

Following revenue records and a one-year promotion.

07 — Education & Certifications

Foundations.

Graduate

M.S., Biology

University of Nebraska, Kearney

Graduate

M.B.A., Business Management

Montgomery University

Undergraduate

B.S., Biology

Mary Washington University

Certification

Six Sigma Black Belt

Villanova University · Certified ISO 9001 Internal Auditor & Trainer

08 — Publications & Affiliations

Beyond the role.

Author

The Pipette Standards Handbook — establishing a liquid-handling standard within the metrology community.

Papers

Multiple papers on liquid handling and gravimetric measurement systems.

Co-Author

Orphan Diseases chapter, RAPS Handbook.

Memberships

Regulatory Affairs Professional Society (RAPS) · Alliance for Regenerative Medicine (ARM) · National Conference of Standards Laboratory (NCSL) · Measurement Science Conference (MSC).

09 — Connect

Let's start a conversation.

Based InGilbertsville, PA
Scan to view this CV online